| Literature DB >> 35094114 |
Serena Giurgola1, Carlotta Casati2,3, Chiara Stampatori4, Laura Perucca3, Flavia Mattioli4, Giuseppe Vallar5,2, Nadia Bolognini5,2.
Abstract
Temporal Binding Window (TBW) represents a reliable index of efficient multisensory integration process, which allows individuals to infer which sensory inputs from different modalities pertain to the same event. TBW alterations have been reported in some neurological and neuropsychiatric disorders and seem to negatively affects cognition and behavior. So far, it is still unknown whether deficits of multisensory integration, as indexed by an abnormal TBW, are present even in Multiple Sclerosis. We addressed this issue by testing 25 participants affected by relapsing-remitting Multiple Sclerosis (RRMS) and 30 age-matched healthy controls. Participants completed a simultaneity judgment task (SJ2) to assess the audio-visual TBW; two unimodal SJ2 versions were used as control tasks. Individuals with RRMS showed an enlarged audio-visual TBW (width range = from - 166 ms to + 198 ms), as compared to healthy controls (width range = - 177/ + 66 ms), thus showing an increased tendency to integrate temporally asynchronous visual and auditory stimuli. Instead, simultaneity perception of unimodal (visual or auditory) events overall did not differ from that of controls. These results provide first evidence of a selective deficit of multisensory integration in individuals affected by RRMS, besides the well-known motor and cognitive impairments. The reduced multisensory temporal acuity is likely caused by a disruption of the neural interplay between different sensory systems caused by multiple sclerosis.Entities:
Keywords: Auditory; Multiple sclerosis; Multisensory integration; Sensory processing; Temporal binding window; Visual
Mesh:
Year: 2022 PMID: 35094114 PMCID: PMC8918188 DOI: 10.1007/s00221-022-06310-0
Source DB: PubMed Journal: Exp Brain Res ISSN: 0014-4819 Impact factor: 1.972
MS participants’ demographic and clinical data
| Patient | Age (years) | Education (years) | Gender | Date of MS diagnosis | EDSS | Drugs | Audiometry | Visual acuity and contrast sensitivity |
|---|---|---|---|---|---|---|---|---|
| #1 | 78 | 7 | F | 2009 | 6.5 | Clonazepam, sativex, pregablin | n.a | Contrast sensitivity 80:20/125* 40: 20/50 1: 20/12.5 |
| #2 | 41 | 18 | F | 1997 | 7 | Baclofen | n.a | Contrast sensitivity 80:20/80* 40: 20/40* 1: 20/16 |
| #3 | 43 | 13 | F | 1998 | 6 | Vitamin C, paroxetine, nadroparin | n.a | Visual acuity: right eye = J3 nat left eye = J3 nat |
| #4 | 56 | 13 | M | 2003 | 6.5 | Paroxetine, gabapentin, triatec, tavor | Normal | Contrast sensitivity 80:20/200* 40: 20/80* 1: 20/25* |
| #5 | 46 | 18 | F | 2002 | 6.5 | Fampridine, setraline, oxybutynin | Normal | Contrast sensitivity 80: N.E 40: 20/125* 1: 20/25* |
| #6 | 46 | 8 | F | 2013 | 7 | Simvastatin, glyatiramer, ketoprofene, clonazepam | Normal | Contrast sensitivity 80:20/80* 40: 20/32 1: 20/16 |
| #7 | 41 | 10 | F | 2000 | 6 | Paroxetine, baclofen, tizanidine, phingolimod, tolterodyne, nimesulid, psyllogel, glicerine | Normal | Contrast sensitivity 80:20/125* 40: 20/25 1: 20/20* |
| #8 | 45 | 16 | M | 1996 | 7 | dexamethasone, Levothyroxine, calcium carbonate, cholecalciferol, zoledronate | Normal | Contrast sensitivity 80:20/80* 40: 20/32 1: 20/16 |
| #9 | 34 | 10 | F | 2009 | 2.5 | Natalizumab | n.a | n.a |
| #10 | 42 | 13 | F | 2002 | 1.5 | No therapy | n.a | n.a |
| #11 | 54 | 8 | F | 2012 | 6.5 | Dibase, melatonin | Normal | Contrast sensitivity 80:20/80* 40: 20/50* 1: 20/10 |
| #12 | 49 | 12 | F | 2010 | 4 | No therapy | n.a | n.a |
| #13 | 39 | 13 | M | 2015 | 4 | No therapy | n.a | n.a |
| #14 | 65 | 18 | M | 2000 | 6.5 | Levothyroxine, amlodipine, oxybutynin, delta-9-tetrahydrocannabinol and cannabidiol | n.a | Contrast sensitivity 80:20/200* 40: 20/125* 1: 20/25* |
| #15 | 52 | 8 | F | 1986 | 4.5 | Theriflunomide | n.a | n.a |
| #16 | 43 | 13 | F | 2010 | 4 | No therapy | n.a | n.a |
| #17 | 50 | 13 | M | 2012 | 6 | Interferon beta-1a | n.a | n.a |
| #18 | 53 | 12 | M | 2003 | 6.5 | ventolin, oxybutynin, phingolimod, omega-3 | Mild bilateral hearing loss for acute frequencies | Contrast sensitivity 80:20/40 40: 20/125* 1: N.E |
| #19 | 41 | 18 | M | 1998 | 7 | Targin, gabapentin, biotin, tysabri | n.a | Visual acuity: right eye = J12 csl left eye = J3 csl |
| #20 | 50 | 13 | F | 1986 | 6 | Mesalazine, extavia (interferon beta-1b) | n.a | n.a |
| #21 | 63 | 18 | F | 1991 | 6.5 | Vitamin D | n.a | n.a |
| #22 | 52 | 15 | M | 1998 | 8 | Targin, gabapentin, fampyra, omeprazole, oxybutynin | n.a | n.a |
| #23 | 42 | 8 | M | 2010 | 1.5 | Copolimer acetate | n.a | n.a |
| #24 | 54 | 18 | M | 2011 | 6 | Fampridine, Ocrelizumab, baclofen, amlodipine | n.a | n.a |
| #25 | 49 | 8 | F | 2017 | 6 | theriflunomide, baclofen, Gabapentin, lactulose, omeprazole | n.a | n.a |
M/F male/female; EDSS expanded disability status scale (ranging from 0 to 10 in 0.5 unit-increments that represent higher levels of disability); n.a. not available
*Abnormal
MS participants’ scores at Rao’s brief repeatable battery (BRB-N) subtests and at mini mental state examination (MMSE)
| BRB-N subtests and MMSE | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Score | SRT-LTS | SRT-CLTR | SRT-D | SPART | SPART-D | SDMT | PASAT 3 | PASAT 2 | WLG | MMSE |
| #1 | Raw | 36 | 19 | 6 | 12 | 5 | 35 | 15 | n.a | 22 | n.a |
| Corrected | 43.6 | 27.3 | 7.1 | 14 | 5.7 | 41.2 | 24.2* | n.a | 19.9 | n.a | |
| #2 | Raw | 58 | 47 | 8 | 22 | 5 | 59 | 50 | 41 | 32 | n.a |
| Corrected | 50.2 | 38.4 | 6.9 | 19.9 | 4.3 | 53.2 | 40.5 | 34.8 | 29.9 | n.a | |
| #3 | Raw | 63 | 51 | 12 | 14 | 8 | 57 | 34 | 26 | 26 | 29 |
| Corrected | 62.2 | 50.1 | 12 | 13.8 | 7.9 | 56.4 | 33 | 25.3 | 23.9 | 27 | |
| #4 | Raw | 28 | 19 | 4 | 28 | 5 | 44 | 55 | 32 | 26 | 29 |
| Corrected | 27.2 | 18.1 | 3.9* | 27.8 | 4.9 | 43.4 | 54 | 31.3 | 28.1 | 26.8 | |
| #5 | Raw | 37 | 33 | 7 | 24 | 8 | 44 | 47 | 31 | 33 | 29 |
| Corrected | 29.15 | 24.4 | 5.8 | 21.9 | 7.28 | 38.2 | 37.5 | 24.8 | 30.9 | 27 | |
| #6 | Raw | 56 | 42 | 8 | 19 | 4 | 42 | 55 | 21 | 26 | 30 |
| Corrected | 62.2 | 48.8 | 8.9 | 20.6 | 4.6 | 46.5 | 60 | 25.9 | 28.1 | 26 | |
| #7 | Raw | 19 | 10 | 9 | 27 | 19 | 34 | 5 | n.a | 19 | 28 |
| Corrected | 20.3* | 12.15* | 9.2 | 27.5 | 16.8 | 35.4* | 7.4* | n.a | 16.9* | 27 | |
| #8 | Raw | 40 | 35 | 9 | 25 | 9 | 56 | 58 | 56 | 30 | 30 |
| Corrected | 35 | 29.5 | 8.3 | 23.7 | 8.5 | 52.3 | 51.9 | 51.9 | 32.1 | 27 | |
| #9 | Raw | 57 | 35 | 6 | 21 | 6 | 52 | 51 | 38 | 29 | n.a |
| Corrected | 60.4 | 38.7 | 6.5 | 21.9 | 6.3 | 54.4 | 55.1 | 40.7 | 26.8 | n.a | |
| #10 | Raw | 45 | 24 | 7 | 17 | 5 | 51 | 52 | 32 | 31 | n.a |
| Corrected | 44.2 | 23.1 | 6.8 | 16.7 | 4.9 | 50.3 | 50.9 | 31.3 | 28.8 | n.a | |
| #11 | Raw | 38 | 34 | 5 | 19 | 7 | 40 | 39 | 35 | 25 | 30 |
| Corrected | 44.2 | 40.8 | 5.9 | 20.6 | 7.6 | 44.5 | 46.5 | 39.9 | 22.9 | 25 | |
| #12 | Raw | 36 | 20 | 6 | 15 | 3 | 40 | 17 | n.a | n.a | n.a |
| Corrected | 36.6 | 20.6 | 6.1 | 15.2 | 3.1* | 40.4 | 17.7* | n.a | n.a | n.a | |
| #13 | Raw | 23 | 7 | 3 | 14 | 5 | 37 | 29 | n.a | 16 | n.a |
| Corrected | 22.2* | 6.8* | 2.9 | 13.6 | 4.6 | 36.5* | 27.5* | n.a | 18.1 | n.a | |
| #14 | Raw | 49 | 39 | 8 | 17 | 7 | 44 | 35 | 30 | 24 | 30 |
| Corrected | 41.15 | 30.4 | 6.9 | 14.3 | 6.3 | 38.2 | 25.5* | 23.8 | 26.1 | 27 | |
| #15 | Raw | 26 | 0 | 2 | 15 | 6 | 34 | n.a | n.a | 12 | n.a |
| Corrected | 32.1 | 0* | 2.9* | 16.6 | 6.6 | 38.2 | n.a | n.a | 9.9* | n.a | |
| #16 | Raw | 37 | 34 | 7 | 26 | 10 | 58 | 58 | 34 | 30 | n.a |
| Corrected | 36.2 | 33.1 | 6.9 | 25.8 | 9.9 | 57.4 | 57 | 33.3 | 27.9 | n.a | |
| #17 | Raw | 9 | 9 | 6 | 16 | 5 | 18 | n.a | n.a | 10 | n.a |
| Corrected | 8.2* | 8.7* | 5.8 | 15.8 | 4.9 | 17.4* | n.a | n.a | 12* | n.a | |
| #18 | Raw | 12 | 0 | 0 | 10 | 6 | 28 | 19 | n.a | 13 | 26 |
| Corrected | 12.8* | 0* | 0* | 10.2* | 6.1 | 28.6* | 20.02* | n.a | 15.1* | 27 | |
| #19 | Raw | 39 | 22 | 5 | 18 | 6 | 41 | 43 | 25 | 28 | n.a |
| Corrected | 31.15 | 13.4* | 3.9* | 15.9 | 5.3 | 35.2* | 33.5 | 18.8 | 30.1 | n.a | |
| #20 | Raw | 33 | 21 | 6 | 17 | 5 | 30 | 27 | n.a | 22 | 27 |
| Corrected | 32.2 | 20.1 | 5.9 | 16.8 | 4.9 | 29.4* | 25.9* | n.a | 19.9 | 27 | |
| #21 | Raw | 31 | 19 | 9 | 14 | 6 | 48 | 16 | n.a | 23 | 30 |
| Corrected | 23.15* | 10.4* | 7.9 | 11.9* | 5.3 | 42.2 | 6.49* | n.a | 20.9 | 26 | |
| #22 | Raw | 22 | 19 | 3 | 8 | 4 | 53 | 53 | 30 | 25 | 29 |
| Corrected | 18.35* | 14.99* | 2.5* | 7.04* | 3.7 | 50.3 | 48.6 | 27.1 | 27.1 | 27 | |
| #23 | Raw | 31 | 28 | 8 | 12 | 4 | 32 | 45 | 28 | 12 | n.a |
| Corrected | 37.2 | 34.8 | 8.9 | 13.6 | 4.6 | 36.5* | 52.5 | 32.9 | 14.1* | n.a | |
| #24 | Raw | 29 | 18 | 5 | 17 | 6 | 51 | 52 | 36 | 32 | n.a |
| Corrected | 21.15* | 9.4* | 3.9* | 14.9 | 5.3 | 45.2 | 42.5 | 29.8 | 34.1 | n.a | |
| #25 | Raw | 26 | 18 | 5 | 11 | 3 | 46 | 33 | n.a | 24 | 29 |
| Corrected | 32.2 | 24.8 | 5.9 | 12.6* | 3.6* | 50.5 | 40.5 | n.a | 21.9 | 27 | |
| Counts (N) | 25 | 25 | 25 | 25 | 25 | 25 | 23 | 15 | 24 | 13 | |
| Mean | 40.95 | 31.44 | 7.08 | 18.61 | 6.36 | 46.82 | 46.93 | 31.44 | 26.18 | 26.67 | |
| Median | 32.2 | 23.1 | 6.1 | 15.9 | 5.3 | 42.2 | 40.5 | 31.3 | 25 | 27 | |
| St. dev | 11.22 | 9.87 | 1.88 | 4.67 | 2.73 | 6.45 | 8.57 | 8.22 | 4.56 | 0.62 | |
| Range | 8.2–62.2 | 0–50.1 | 0–12 | 7.04–27.8 | 3.7–16.8 | 17.4–57.4 | 6.49–60 | 18.8–51.9 | 9.9–34.1 | 25–27 | |
SRT-LTS select reminding test-long-term storage; SRT-CLTR select reminding test-consistent long-term retrieval; SRT-D select reminding test-delayed recall; SPART spatial recall test; SPART-D spatial recall test-delayed recall; SDMT symbol digit modalities test; PASAT 3/2 3/2 s-intervals paced auditory serial addition task; WLG word list generation; MMSE mini mental state examination; St. dev. standard deviation; n.a. not available
*Pathological score (performance below the cut-off)
Fig. 1Experimental trials. Examples of experimental trials in the SJ2 task, during which pairs of stimuli with various stimulus onset asynchrony (SOA; 17 SOAs = 0, ± 50, ± 100, ± 150, ± 200, ± 250, ± 300, ± 350, ± 400 ms;—means auditory first, + visual first) were presented. (A) In the bimodal SJ2 task, an Auditory stimulus (A) was presented with a Visual stimulus (V); AV = auditory first (SOAs with negative values), VA = visual first (SOAs with positive values). (B, C) In the unimodal SJ2 task, 2 visual or 2 auditory stimuli were presented with 9 SOAs (from 0 to 400 ms)
Fig. 2Bimodal SJ2 task. Psychometric fitting of a representative subject
Fig. 3Results from the bimodal SJ2 task. Participants affected by RRMS (black line and arrow) show an enlarged audio-visual TBW (from − 166 to + 198 ms; − means auditory stimulus first, + visual first), as compared to healthy controls (grey line and arrow; from − 177 to + 66 ms). Higher proportion of simultaneity perceptions were detected when the visual stimulus preceded the auditory stimulus by + 100 ms to + 350 ms, as compared to healthy controls (all ps < 0.03)
Fig. 4Point of subjective simultaneity (PSS) distribution in the bimodal SJ2 task. As compared to healthy controls (left panel), participants affected by RRMS (right panel) show a greater variability with respect to the number of SOAs where the visual and auditory stimuli were perceived as simultaneous
Fig. 5Results from the unimodal SJ2 tasks. Unimodal (mean responses at the visual and auditory tasks) simultaneity perception differs between RRMS (black line) and healthy participants (grey line) only when stimuli are presented at the very short SOA of 50 ms (p < 0.001), with participants affected by RRMS being more prone to report simultaneity with such short delay
Correlational analyses between MS participants’ score at Rao’s brief repeatable battery (BRB-N) subtests, mini mental state examination (MMSE), expanded disability status scale (EDSS) and the width of the multisensory temporal binding window (TBW)
| Entire TBW | Right side TBW | Left side TBW | ||
|---|---|---|---|---|
| SRT-LTS | Pearson’s | 0.108 0.607 | 0.044 0.833 | -0.090 0.670 |
| SRT-CLTR | Pearson’s | − 0.219 0.293 | − 0.213 0.307 | − 0.029 0.892 |
| SRT-D | Pearson’s | − 0.194 0.353 | − 0.265 0.201 | − 0.155 0.459 |
| SPART | Pearson’s | − 0.468* 0.018 | − 0.246 0.236 | 0.296 0.151 |
| SPART-D | Pearson’s | − 0.354 0.082 | − 0.369 0.070 | − 0.087 0.678 |
| SDMT | Pearson’s | − 0.123 0.559 | − 0.068 0.748 | 0.072 0.732 |
| PASAT 3 | Pearson’s | − 0.163 0.457 | 0.021 0.922 | 0.265 0.222 |
| PASAT 2 | Pearson’s | − 0.260 0.348 | − 0.306 0.268 | − 0.144 0.609 |
| WLG | Pearson’s | − 0.219 0.303 | − 0.063 0.769 | 0.251 0.237 |
| MMSE | Pearson’s | 0.456 0.118 | 0.221 0.469 | − 0.336 0.262 |
| EDSS | Pearson’s | − 0.399* 0.048 | − 0.513* 0.009 | − 0.265 0.200 |
SRT-LTS select reminding test-long-term storage; SRT-CLTR select reminding test-consistent long-term retrieval; SRT-D select reminding test-delayed recall; SPART spatial recall test; SPART-D spatial recall test-delayed recall; SDMT symbol digit modalities test; PASAT 3/2 3/2 s-intervals paced auditory serial addition task; WLG word list generation; MMSE mini mental state examination; EDSS expanded disability status Scale
*Significant correlation